“Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s46. doi:10.25251/skin.4.supp.46.